Skip to main content

Medication Treatments

In a study of OUD patients following their transition from two Phase 3 clinical trials of Sublocade, 44% of participants self-reported sustained illicit opioid-free weeks for the duration of the project.
Marc Fishman, MD, of Maryland Treatment Centers and the Johns Hopkins University School of Medicine, discusses new formulations of medicines to treat OUD and delivery strategies during the COVID-19 pandemic.
Braeburn has requested final approval from the U.S. Food and Drug Administration for Brixadi, an injectable form of buprenorphine with weekly and monthly formulations.
In a study of mice, a synthetic molecule was found to reduce cocaine and methamphetamine consumption and cravings without the side effects typically associated with other interventions, according to research published Thursday in the journal Cell.
A long-term safety study of extended-release buprenorphine illustrates a safety profile comparable to that of the sublingual version of the drug.
Back to Top